Ria Health (“Ria” or the “Company”), a leading telehealth provider of evidence-based alcohol use disorder (AUD) treatment, today announced the closing of a Series B growth equity round led by Peloton Equity, LLC (“Peloton”), with participation from existing investors including SV Health Investors (“SV”), BPEA Private Equity, and SOSV.
The Company will use the new capital to continue scaling its clinical model and payor coverage, accelerate investments in sales and marketing, and enhance Ria’s differentiated position as a value-add partner in the continuum of AUD care.
Ria delivers AUD treatment nationally, rooted in an evidence-based clinical model that combines medication assisted treatment, behavioral therapy, and coaching. The Company’s industry leading outcomes are driven by a physician-led clinical team and a program designed to meet patients where they are – seeking either harm reduction or abstinence from alcohol. Ria’s focus on the best outcome and experience for the patient, and significant reduction in medical spend for its payor partners, has also led the Company to partner with facility-based AUD providers and AUD-focused digital health companies.
“This investment represents a critical milestone for Ria as we continue to innovate and grow as a leader within AUD treatment,” said Bill Stapleton, CEO of Ria Health. “We are excited to have investor partners that share our vision for a more integrated, evidence-based, and patient-focused continuum of care for alcohol use disorder.”
Ria’s value-based payor arrangements align incentives around improvements in key quality metrics and a phased approach to service utilization. Ria currently has contracts with 15 payors and provides care via telehealth across all 50 states, offering greater patient access and convenience yielding improved clinical outcomes.
With this funding round, Michael O’Rourke, Partner at Peloton Equity, will join Ria Health’s Board of Directors. Ria’s Board of Directors includes Carol Vallone, Chair of the Board of Trustees at McLean Hospital; Dr. Martin Rosenzweig, former Chief Medical Officer (Behavioral) at UnitedHealthGroup; Michael Balmuth, Managing Partner at SV; Dr. John Mendelson, founder and Chief Medical Officer of Ria; and Bill Stapleton, CEO of Ria.
“Ria’s business model and AUD-focused clinical program produce unparalleled access to specialized, cost-effective treatment and incredible patient outcomes,” said Michael O’Rourke. “The Company has already demonstrated strong momentum on the path to transforming the AUD treatment industry, and we look forward to supporting its continued innovation and growth.”
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
